3/20
01:49 pm
imvt
Rating for IMVT
Low
Report
Rating for IMVT
3/20
01:49 pm
imvt
Rating for IMVT
Low
Report
Rating for IMVT
3/20
09:00 am
imvt
Immunovant (IMVT) is now covered by Sanford C. Bernstein. They set a "market perform" rating and a $28.00 price target on the stock.
Low
Report
Immunovant (IMVT) is now covered by Sanford C. Bernstein. They set a "market perform" rating and a $28.00 price target on the stock.
3/19
04:18 pm
imvt
Immunovant initiated with a Market Perform at Bernstein
Medium
Report
Immunovant initiated with a Market Perform at Bernstein
3/19
04:18 pm
imvt
Immunovant initiated with a Market Perform at Bernstein
Medium
Report
Immunovant initiated with a Market Perform at Bernstein
2/10
08:05 am
imvt
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
2/9
09:43 am
imvt
Rating for IMVT
Low
Report
Rating for IMVT
2/9
09:43 am
imvt
Rating for IMVT
Low
Report
Rating for IMVT
2/9
07:20 am
imvt
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
2/9
07:20 am
imvt
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Immunovant (NASDAQ:IMVT) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/6
08:21 am
imvt
Rating for IMVT
Low
Report
Rating for IMVT
1/6
08:21 am
imvt
Rating for IMVT
Low
Report
Rating for IMVT
1/6
08:02 am
imvt
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
Medium
Report
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
1/6
08:02 am
imvt
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
Medium
Report
Immunovant (NASDAQ:IMVT) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating.
1/6
07:44 am
imvt
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
Low
Report
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
1/6
07:44 am
imvt
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
Low
Report
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research